+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea



First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea



Antimicrobial Agents and ChemoTherapy 49(11): 4809-4810




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049087003

Download citation: RISBibTeXText

PMID: 16251340

DOI: 10.1128/aac.49.11.4809-4810.2005


Related references

Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea. Journal of Clinical Microbiology 37(6): 1758-1763, 1999

Investigation of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli in Korea. Letters in Applied Microbiology 39(1): 41-47, 2004

Observation on integron carriage among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Indian Journal of Medical Microbiology 28(3): 207-210, 2010

Dissemination of SHV-12 and CTX-M-type extended-spectrum beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. Journal of Antimicrobial ChemoTherapy 56(4): 698-702, 2005

Molecular characteristics of extended spectrum beta-lactamases in Escherichia coli and Klebsiella pneumoniae and the prevalence of qnr in Extended spectrum beta-lactamase isolates in a tertiary care hospital in Korea. Yonsei Medical Journal 51(5): 768-774, 2010

Activity of nine antimicrobial agents against clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and deficient or not in porins. Journal of Antimicrobial ChemoTherapy 46(5): 858-859, 2000

CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea. Fems Microbiology Letters 245(1): 93-98, 2005

Prevalence of SHV-12 among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and identification of a novel AmpC enzyme (CMY-8) in Southern Taiwan. Antimicrobial Agents and ChemoTherapy 44(6): 1438-1442, 2000

Prevalence of Shv-12 among Clinical Isolates of Klebsiella pneumoniae Producing Extended-Spectrum beta -Lactamases and Identification of a Novel AmpC Enzyme (Cmy-8) in Southern Taiwan. Antimicrobial Agents and Chemotherapy 44(6): 1438-1442, 2000

Survey of Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-2a in Korea. Journal of Clinical Microbiology 36(5): 1446-1449, 1998

Resistance to gentamicin, amikacin and ciprofloxacin among nosocomial isolates of klebsiella pneumoniae subspecie pneumoniae producing extended spectrum beta-lactamases. Revista Medica de Chile 132(10): 1173-1178, 2004

Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrobial Agents and ChemoTherapy 42(1): 53-58, 1998

Characterization of AmpC, CTX-M and MBLs types of β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli producing Extended Spectrum β-lactamases in Kerman, Iran. Jundishapur Journal of Microbiology 7(2): E8756, 2014

An outbreak of a CTX-M-type beta-lactamase-producing Klebsiella pneumoniae: The importance of using cefpodoxime to detect extended-spectrum beta-lactamases. Journal of Antimicrobial Chemotherapy 51(1): 195-196, 2003

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrobial Agents and ChemoTherapy 55(5): 2434-2437, 2011